What Is Hyperlipidemia? Causes, Diagnosis & Treatment

Hyperlipidemia means having abnormal levels of fats, or lipids, in the blood. In everyday use, people often use the term to describe high cholesterol, but the condition can involve several different abnormalities: elevated low-density lipoprotein cholesterol (LDL-C), elevated triglycerides, elevated non-HDL cholesterol, or combinations of these. Modern guidelines increasingly use the broader term dyslipidemia because cardiovascular risk is influenced by more than total cholesterol alone.

Hyperlipidemia matters because some lipoprotein particles can contribute to the buildup of atherosclerotic plaque inside arteries. Over time, this process can increase the risk of heart attack, ischemic stroke, and other forms of atherosclerotic cardiovascular disease (ASCVD). The condition usually causes no symptoms, so a blood test is often the only way to know it is present.

The 2026 American College of Cardiology/American Heart Association guideline on dyslipidemia updated many parts of cholesterol management, including earlier risk assessment, renewed LDL-C and non-HDL-C treatment goals, wider use of lipoprotein(a) testing, selective apolipoprotein B testing, and use of the PREVENT-ASCVD equations for primary-prevention risk estimation. This article explains what hyperlipidemia is, why it develops, how it is diagnosed, how statins work, and how current treatment decisions are made.

What Does Hyperlipidemia Mean?

Blood contains several types of lipids and lipoproteins. Cholesterol itself is essential for normal cell membranes, hormone production, bile acids, and other biological functions. The problem is not that cholesterol exists; the problem is when certain cholesterol-carrying particles are present at levels that increase long-term cardiovascular risk.

The most familiar measurements on a lipid panel are:

LDL cholesterol (LDL-C): often called “bad” cholesterol because higher levels are strongly associated with atherosclerotic cardiovascular disease.
HDL cholesterol (HDL-C): often called “good” cholesterol, although modern risk assessment does not treat HDL as a simple protective target that should be raised with medication.
Triglycerides: a form of fat used for energy. Very high levels can increase the risk of pancreatitis, while more moderate elevations may also signal increased cardiovascular risk.
Total cholesterol: a combined measure that includes cholesterol carried in several types of lipoproteins.
Non-HDL cholesterol: total cholesterol minus HDL cholesterol; it reflects cholesterol carried by atherogenic particles.

The 2026 dyslipidemia guideline also emphasizes two additional markers in selected patients: lipoprotein(a), or Lp(a), and apolipoprotein B, or ApoB. These can identify risk that may not be fully captured by a standard lipid profile.

Hyperlipidemia vs. Hypercholesterolemia vs. Dyslipidemia

These terms overlap but are not identical.

Hypercholesterolemia usually refers specifically to elevated cholesterol, especially LDL-C.
Hypertriglyceridemia refers to elevated triglycerides.
Hyperlipidemia can refer broadly to elevated blood lipids.
Dyslipidemia is broader still and can describe an unhealthy pattern of lipid or lipoprotein levels, including elevated LDL-C, elevated triglycerides, or other abnormalities.

The updated 2026 ACC/AHA guideline deliberately uses the term dyslipidemia because risk assessment now considers several atherogenic lipoproteins rather than LDL-C in isolation.

Why High LDL Cholesterol Matters

LDL particles carry cholesterol through the bloodstream. When LDL concentrations remain elevated over many years, cholesterol-containing particles can enter the artery wall and contribute to atherosclerotic plaque.

Atherosclerosis develops gradually. Plaque can narrow arteries or become unstable and rupture, triggering blood-clot formation. Depending on where this occurs, the result may be a heart attack, ischemic stroke, or reduced blood flow to other parts of the body.

This is why cardiovascular prevention is increasingly focused on cumulative exposure. A moderately elevated LDL-C that persists for decades can matter even if a person feels completely well.

What Causes Hyperlipidemia?

Hyperlipidemia usually results from a combination of genetics, lifestyle, age, other medical conditions, and medications.

Dietary Patterns

The National Heart, Lung, and Blood Institute notes that diets high in saturated fat can increase LDL cholesterol. Saturated fat is found in foods such as fatty meats, butter, full-fat dairy products, and some tropical oils.

Dietary cholesterol can affect blood cholesterol in some people, but saturated fat and overall dietary pattern are usually more important targets. A heart-healthy eating pattern generally emphasizes vegetables, fruits, whole grains, legumes, nuts, seeds, fish, and unsaturated fats while limiting saturated fat, trans fat, and heavily processed foods.

Physical Inactivity

Low levels of physical activity are associated with poorer cardiovascular health and can contribute indirectly through weight gain, insulin resistance, triglyceride elevation, blood-pressure changes, and lower cardiorespiratory fitness.

Smoking

Smoking damages blood vessels and increases cardiovascular risk independently of cholesterol. It can also adversely affect lipid patterns. For someone with hyperlipidemia, smoking substantially compounds the risk created by atherogenic lipoproteins.

Excess Body Weight and Metabolic Disease

Overweight, obesity, insulin resistance, and type 2 diabetes can contribute to elevated triglycerides and other atherogenic lipid patterns. Diabetes is particularly important because cardiovascular-risk management often includes both glucose control and aggressive management of LDL-C and other risk factors.

For background on diabetes physiology, see our article on type 1 diabetes and associated pathophysiology.

Genetics

Some people inherit genetic variants that cause very high LDL cholesterol even when they follow a healthy lifestyle. One important inherited condition is familial hypercholesterolemia (FH).

FH can cause lifelong exposure to high LDL-C and markedly increase the risk of premature ASCVD if it is not recognized and treated. A strong family history of very high cholesterol or heart attack at a young age should prompt medical evaluation.

Other Medical Conditions

Secondary causes of dyslipidemia can include hypothyroidism, chronic kidney disease, liver disease, diabetes, and other metabolic disorders. Treating the underlying condition may improve the lipid profile.

Medications

Some medications can alter cholesterol or triglyceride levels. A clinician evaluating unexpected dyslipidemia will usually review prescription drugs, over-the-counter medications, and supplements as part of the assessment.

Does Hyperlipidemia Cause Symptoms?

Most people with high cholesterol have no symptoms. A person can have substantially elevated LDL-C for years without feeling different.

Very severe inherited lipid disorders can sometimes produce visible signs such as xanthomas, which are cholesterol-rich deposits in the skin or tendons. These are not common in ordinary mild-to-moderate hyperlipidemia.

Because symptoms are unreliable, screening is essential.

How Hyperlipidemia Is Diagnosed

Diagnosis begins with a lipid blood test, usually called a lipid panel. A clinician may also review medical history, family history, blood pressure, smoking status, diabetes, kidney function, medications, and other cardiovascular-risk factors.

A lipid panel commonly reports total cholesterol, LDL-C, HDL-C, and triglycerides. Depending on the situation, additional tests may include Lp(a), ApoB, thyroid studies, blood glucose or A1C, liver tests, kidney tests, or other measurements.

Does the Test Have to Be Fasting?

Not every cholesterol test requires fasting. Nonfasting lipid measurements are often adequate for routine cardiovascular-risk assessment. A clinician may request a fasting test when triglycerides are very high, when a previous result is difficult to interpret, or when a more precise assessment is needed.

Lipoprotein(a): Why the 2026 Guideline Gives It More Attention

Lipoprotein(a), written as Lp(a), is an LDL-like particle whose concentration is strongly influenced by genetics. Elevated Lp(a) is associated with increased cardiovascular risk and can help explain why some people develop ASCVD even when their standard cholesterol numbers do not appear extremely abnormal.

The 2026 ACC/AHA guideline recommends measuring Lp(a) at least once in a lifetime for cardiovascular-risk assessment. Because levels are largely genetically determined, repeated testing is not always necessary unless a clinician has a specific reason.

What Is ApoB?

Apolipoprotein B is a protein present on atherogenic particles including LDL and several triglyceride-rich particles. Measuring ApoB can provide an estimate of the number of atherogenic particles rather than simply the amount of cholesterol they contain.

The 2026 guideline identifies ApoB as particularly useful in situations such as elevated triglycerides, diabetes, or very low achieved LDL-C where a standard lipid panel may underestimate residual particle-related risk.

Cardiovascular Risk Is More Than One Cholesterol Number

Treatment is not based solely on whether LDL-C is above a single cutoff. Clinicians consider the person’s overall risk.

Important factors can include:

age;
blood pressure;
smoking;
diabetes;
kidney disease;
family history of premature cardiovascular disease;
LDL-C level and duration of exposure;
Lp(a) or ApoB when appropriate;
existing cardiovascular disease;
coronary artery calcium in selected adults.

For primary prevention in adults ages 30 to 79, the 2026 guideline recommends the American Heart Association’s PREVENT-ASCVD equations rather than the older Pooled Cohort Equations.

What Is Coronary Artery Calcium Scoring?

A coronary artery calcium, or CAC, scan uses computed tomography to look for calcified plaque in the coronary arteries. It is not necessary for everyone.

In selected people whose decision about cholesterol-lowering medication remains uncertain after standard risk assessment, a CAC score may help reclassify risk. A higher score indicates a greater burden of calcified coronary atherosclerosis.

CAC testing should be used through clinician–patient decision-making because it involves radiation exposure, cost, and interpretation within the person’s broader risk profile.

Lifestyle Treatment for Hyperlipidemia

Lifestyle management remains a foundation of dyslipidemia treatment even when medication is needed.

Choose More Unsaturated Fats

Replacing saturated fats with unsaturated fats can improve LDL-C. Foods such as nuts, seeds, olive oil, avocado, and fish can be part of a heart-healthy dietary pattern.

Increase Soluble Fiber

Oats, barley, beans, lentils, apples, citrus fruits, and other fiber-rich foods can support healthy cholesterol levels. Soluble fiber can reduce intestinal absorption of cholesterol and bile acids.

Exercise Regularly

Regular physical activity supports cardiovascular health, blood pressure, insulin sensitivity, body-weight management, and triglyceride control.

Avoid Smoking

Stopping smoking reduces cardiovascular risk regardless of the cholesterol level and is one of the most important preventive steps a smoker can take.

Limit Excess Alcohol

Excess alcohol can substantially raise triglycerides in some people. Anyone with very high triglycerides should discuss alcohol intake with a clinician.

Manage Weight and Metabolic Health

When excess body weight, insulin resistance, or type 2 diabetes contributes to dyslipidemia, sustainable weight loss and metabolic management can improve triglycerides and other risk factors.

How Statins Work

Statins remain the foundation of lipid-lowering drug therapy for many patients because they have extensive evidence for reducing heart attack, stroke, and other ASCVD events.

Examples include atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, and pitavastatin.

Statins inhibit HMG-CoA reductase, an enzyme involved in cholesterol synthesis in the liver. Reduced hepatic cholesterol production causes liver cells to increase LDL receptors on their surface. Those receptors remove more LDL particles from the bloodstream, lowering circulating LDL-C.

This receptor effect is central. The older version of this article described statins as competing because they have “the same molecular structure” as the enzyme; that description was inaccurate. Statins inhibit the enzyme’s activity and ultimately increase hepatic clearance of LDL from blood.

Who May Be Offered a Statin?

Statin decisions depend on age, LDL-C, existing ASCVD, diabetes, estimated risk, family history, and other factors.

Current guidance supports earlier treatment for people with prolonged exposure to atherogenic lipoproteins. The 2026 guideline, for example, says pharmacologic therapy may be considered in young adults with LDL-C of at least 160 mg/dL or a strong family history of premature ASCVD.

People who already have established ASCVD are generally treated more aggressively because their risk of another event is higher.

LDL Targets in the 2026 Guideline

The 2026 ACC/AHA guideline brings back explicit LDL-C and non-HDL-C goals in addition to percentage LDL reduction.

For patients with ASCVD who are at very high risk, the guideline recommends an LDL-C goal below 55 mg/dL and non-HDL-C below 85 mg/dL. Some patients with ASCVD who are not at very high risk have an LDL-C goal below 70 mg/dL.

These are treatment targets for specific clinical risk groups, not universal goals that everyone should try to reach without medical guidance.

What If a Statin Is Not Enough?

When LDL-C remains above the appropriate goal despite maximally tolerated statin therapy, clinicians may add another lipid-lowering medication.

Options can include:

ezetimibe, which reduces intestinal cholesterol absorption;
PCSK9-targeting therapies, which increase LDL-receptor availability and can substantially lower LDL-C;
bempedoic acid, an oral cholesterol-lowering medication used in selected patients;
other therapies chosen according to the lipid disorder, cardiovascular risk, tolerance, cost, and clinical context.

The goal is not to add medication automatically. The treatment plan should match the person’s absolute risk and the amount of LDL reduction needed.

Statin Side Effects: What the Evidence Supports

The older article listed neuropathy, pancreatic dysfunction, sexual dysfunction, CoQ10 depletion, memory loss, and diabetes as if they were typical statin consequences. That presentation overstated or mixed evidence of very different quality.

The most frequently discussed adverse effect is muscle symptoms, although muscle pain is common in the general population and not every symptom experienced while taking a statin is caused by the drug. Severe muscle breakdown, or rhabdomyolysis, is rare.

Statins can cause elevations in liver enzymes, while serious liver injury is uncommon. They are also associated with a small increase in the risk of developing type 2 diabetes in susceptible people. For patients who have a clear indication for statin treatment, the reduction in cardiovascular events generally outweighs this risk.

Concerns about cognition have been studied extensively. Current evidence does not support treating routine memory loss as an expected statin toxicity.

What Is Statin Intolerance?

Some patients cannot tolerate a particular statin or dose. Clinicians may respond by checking for other causes of muscle symptoms, reviewing interacting medications, changing the statin, reducing the dose, using intermittent dosing in selected cases, or combining a lower statin dose with a nonstatin medication.

Stopping therapy permanently without discussing alternatives can leave cardiovascular risk untreated.

Hypertriglyceridemia

High triglycerides require somewhat different thinking from high LDL-C.

Moderate triglyceride elevations often occur with obesity, diabetes, alcohol use, high intake of refined carbohydrates, kidney disease, or certain medications. Lifestyle changes and statin therapy may be used primarily to reduce ASCVD risk.

At very high levels, particularly around or above 1,000 mg/dL, the immediate concern includes pancreatitis. The 2026 guideline notes that triglyceride-lowering therapies may be needed in addition to lifestyle intervention, especially when levels are severe.

Familial Hypercholesterolemia

Familial hypercholesterolemia deserves special attention because LDL-C can be very high from childhood onward.

Clues include:

very high LDL-C;
heart attack or coronary disease at an unusually young age;
multiple relatives with high cholesterol;
known FH in a parent, sibling, or child;
physical signs such as tendon xanthomas in some cases.

Because FH runs in families, diagnosis in one person may lead clinicians to recommend screening close relatives.

A Practical Hyperlipidemia Case Example

Consider an older adult with diabetes, hypertension, and elevated LDL-C. The previous version of this article concluded that statins were appropriate largely because the patient was elderly and diabetic.

A modern assessment would be more systematic. The clinician would determine whether the patient already has ASCVD, review LDL-C and triglyceride levels, assess kidney function and other risk factors, review medications, discuss lifestyle, and determine the intensity of lipid-lowering therapy needed.

If the person already had a prior heart attack or stroke, treatment targets would generally be more aggressive than for a person with no known ASCVD. If LDL-C remained above goal on a tolerated statin, additional therapy might be considered.

This illustrates why hyperlipidemia treatment cannot be decided from age or one laboratory value alone.

Do Fish-Oil Supplements Treat High Cholesterol?

Fish-oil products can lower triglycerides, but over-the-counter supplements should not be assumed to provide the same cardiovascular benefit as prescription therapies studied in clinical trials. Some formulations can also increase LDL-C.

Our older article on fish-oil supplements discusses the topic more broadly, but anyone using omega-3 products specifically to treat dyslipidemia should discuss the exact formulation and dose with a clinician.

When to Talk With a Clinician

Medical review is particularly important if:

LDL-C is markedly elevated;
triglycerides are very high;
you have diabetes, kidney disease, or known cardiovascular disease;
a close relative had a heart attack or stroke at a young age;
familial hypercholesterolemia is suspected;
you are experiencing possible medication side effects;
you are considering stopping a prescribed lipid-lowering medication.

This article is educational and cannot replace individualized medical care.

Conclusion

Hyperlipidemia is not simply “too much cholesterol.” It is a group of lipid and lipoprotein abnormalities that can increase long-term risk of atherosclerotic cardiovascular disease.

Current management combines lifestyle measures with individualized risk assessment and, when appropriate, medications. Statins remain the main pharmacologic treatment for many patients because they lower LDL-C and reduce cardiovascular events. Newer guidance also places greater emphasis on Lp(a), ApoB, coronary calcium, lifetime exposure, and treatment goals based on risk.

The most important practical point is that high cholesterol is usually silent. Testing, understanding the complete risk profile, and choosing treatment in partnership with a clinician are more reliable than waiting for symptoms.